GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Agenus AGEN · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.14

-4.06%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Agenus — daily AGEN Delayed
Market value
$131.8m
Last close × shares
Volume
815.6k
Shares, 19 Nov 2026

About Agenus

From its filings with the US Securities and Exchange Commission

SEC filings

Agenus is based in Lexington, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AGEN. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $114.2m and a net loss of $3.1m. At that date it held total assets of $226.8m and shareholders' equity of −$271.1m. By region, United States [Member] accounted for 99.1%, followed by Rest of World [Member] at 0.9%.

In its own words

Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Our primary business is immuno-oncology ("I-O"), where we are advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients who may benefit from immunotherapy. Our lead clinical program is botensilimab (“BOT” or “AGEN1181”), alone and in combination with balstilimab (“BAL”). We also maintain select clinical-stage immuno-oncology assets, which may be used as standalone agents or be complimentary to botensilimab plus balstilimab (“BOT/BAL”). Agenus also maintains an equity investment in MiNK Therapeutics, Inc. ("MiNK"), with an approximate fair value of $24.3 million as of December 31, 2025, and a majority ownership of a vaccine adjuvant business through our subsidiary SaponiQx, Inc. ("SaponiQx").

Our strategy is to focus capital on execution of programs that we believe have the clearest path to meaningful clinical and commercial value, led by BOT/BAL in colorectal cancer and selected other tumor types. We intend to advance late-stage development and support responsible paid patient access programs as well as clinical trials. We maintain manufacturing flexibility through strategic collaborations with an emphasis on our Zydus collaboration.

Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗

More about Agenus →

How it makes its money

Revenue, year to 31 Dec 2025

  • Non Cash Revenue Related To Sale Of Future Royalties [Member] $108.6m · 95.1%
  • Non-cash royalty revenue. $108.6m · 95.1%
  • Pre Commercial Product Revenue [Member] $4.2m · 3.7%
  • Other [Member] $1.0m · 0.9%

Latest on Agenus

Our reporting

Next results

15 Mar 2027

Due on 15 Mar 2027. Analysts expect earnings of -0.22 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Agenus's ticker?

Agenus trades as AGEN on its US listing, under ISIN US00847G8042.

What was Agenus's last closing price?

6.14 on 19 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.